Delivery Order 75N95018G00019-75N95020F00001

Award Date 3/25/20
Potential Completion Date 12/24/21
Potential Value $1.2M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
West Menlo Park, CA 94025, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a Cost Plus Fixed Fee delivery order contract to SRI International, a non-profit research and development institute. The $1,256,044.00 contract is for GLP (Good Laboratory Practice) interaction safety studies in rats and dogs, under an Indefinite Delivery Indefinite Quantity (IDIQ) contract vehicle. The contract is not set aside for any specific business type. SRI International...
This federal contract award, with a ceiling value of $1,927,163.66, was issued by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services. The contract was awarded to SRI International, a non-profit research and development organization, and is part of NIDA's Pharmacology and Toxicology for Neurotherapeutics Program (PTNP). The contract, which is a Delivery Order under the PTNP Indefinite Delivery Vehicle (IDV), is for IND-enabling studies....
This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), a component of the Department of Health and Human Services, to SRI International, a non-profit research institute. The $3,698,818.25 contract is for non-clinical absorption, distribution, metabolism, and excretion (ADME) studies, with a period of performance from September 19, 2016 to September 18, 2021. This award does not have a small business set-aside. SRI International, as the prime...
Sri International has been awarded a cost-plus-fixed-fee delivery order valued at $571,190 by the National Institute on Drug Abuse (NIDA), a component of the Department of Health and Human Services (HHS), to conduct Task Order 01 for Cocaine Interaction Safety Studies in Rats under the Toxicological Evaluations of Potential Medications IDIQ. The ordering period is from September 12, 2023 through September 11, 2024. The place of performance is West Menlo Park, California. No set-aside designation...
This task order was awarded by the National Institutes of Health (NIH), a component of the Department of Health and Human Services (HHS), to the non-profit research institute SRI International. The $531,805.00 task order is for interaction safety studies in rats using whole body plethysmography, supporting the NIH's National Institute on Drug Abuse's toxicological evaluations of potential medications program. The period of performance is from August 1, 2019 to July 31, 2020, with a current...
This task order was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to SRI International, a non-profit research institute, for an expanded study on acute toxicology for a radiotracer under the NIMH Toxicological Evaluation of Novel Ligands Program. The task order has a firm fixed price of $203,534 and a completion date of September 30, 2021. It is not designated as a set-aside contract. SRI International has...
This is a federal contract award from the National Institute on Drug Abuse (NIDA), a civilian agency, to SRI International, a non-profit research and development organization. The contract is an administrative task order under the Pharmacology and Toxicology for Neurotherapeutics Program (PTNP) indefinite delivery vehicle (IDV). The total ceiling value of this award is $106,072.00, and the period of performance is from September 13, 2015 to September 12, 2016. The contract is a...
This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the U.S. Department of Health and Human Services. The contract, valued at $11,883,375.62, was awarded on December 15, 2002 to Sri International, a non-profit research and development institute, for the purpose of de-obligating FY2006 funds. The contract has a period of performance through December 31, 2009 and is being performed in West Menlo Park, CA. Sri...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to SRI International, a non-profit research and development institute. The contract, worth $138,512.00, is for acute toxicology testing of a radiotracer for cyclooxygenase-1 (COX-1) during the performance period of June 30, 2015 to June 29, 2016. This contract is not set aside for any particular business category. SRI International has a...
This is a federal contract award from the National Institute on Drug Abuse (NIDA), a civilian agency, to SRI International, a non-profit research and development institute. The contract is for $403,254.01 and is part of NIDA's Pharmacology and Toxicology for Neurotherapeutics Program (PTNP). The contract is for "Pharmacokinetics and Toxicology Studies - Buckpitt LDT" and is a Cost Plus Fixed Fee delivery order. The contract does not have a set-aside designation. SRI International is...
  • 75N95018G00019
    Basic Ordering Agreement
  • 75N95018G00019-75N95020F00001
    Delivery Order

This is a cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse (NIDA) to SRI International, a nonprofit research and development institute. The purpose of the contract is to conduct purpose interaction safety studies in rats and dogs, with a period of performance from March 25, 2020 to March 24, 2021. The total potential value of the contract is $1,206,338.00. The contract is part of NIDA's Major Program Code for Toxicological Evaluations of Potential Medications and does not have a set-aside designation. SRI International has conducted substantial research and development work for various federal agencies, including the Department of Defense, NASA, and HHS components.

Generated 5/24/24, 10:53 AM